Adrenocortical carcinoma (ACC) is an aggressive cancer with poor long-term survival. Apart from radical surgery, there is a reduced range of therapeutic possibilities and mitotane remains the cornerstone of the treatment in adjuvant and palliative setting. Even though many decades after its introduction in clinical practice, there are still many uncertainties surrounding the applied use and the actual benefit of this old drug. Recent ACC guidelines suggest adjuvant mitotane for patients at high risk of recurrence, and chemotherapy plus mitotane in metastatic disease, moreover the use of mitotane monotherapy has been proposed in a subset of patients. When using mitotane, physicians have to consider and manage its potential toxicity and endocrine effects that need a complex supporting therapy.

Mitotane: new facts for an old drug

CALABRESE, ANNA
Co-first
;
PUGLISI, SORAYA
Co-first
;
V. Basile;P. Perotti;M. Terzolo
Last
2019-01-01

Abstract

Adrenocortical carcinoma (ACC) is an aggressive cancer with poor long-term survival. Apart from radical surgery, there is a reduced range of therapeutic possibilities and mitotane remains the cornerstone of the treatment in adjuvant and palliative setting. Even though many decades after its introduction in clinical practice, there are still many uncertainties surrounding the applied use and the actual benefit of this old drug. Recent ACC guidelines suggest adjuvant mitotane for patients at high risk of recurrence, and chemotherapy plus mitotane in metastatic disease, moreover the use of mitotane monotherapy has been proposed in a subset of patients. When using mitotane, physicians have to consider and manage its potential toxicity and endocrine effects that need a complex supporting therapy.
1
24
https://www.sciencedirect.com/science/article/pii/S2451965019300675?via=ihub
A.Calabrese,S.Puglisi,V.Basile,P.Perotti,M.Terzolo
File in questo prodotto:
File Dimensione Formato  
Mitotane new facts.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 662.8 kB
Formato Adobe PDF
662.8 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1719510
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact